November 5, 2014 — Signs of new growth in obesity treatment options are appearing at ObesityWeek 2014 in Boston this week. Novo Nordisk presented a sweeping scope of results on Tuesday from clinical trials with its drug, liraglutide, which is awaiting final approval from FDA. Researchers are presenting new data for other obesity treatments — lorcaserin, bupropion/naltrexone, and phenteramine/topiramate — that […]
November 4, 2014 — Questions about the evidence for action to reduce the impact of obesity were at the center of a thoughtful and lively advocacy forum yesterday at ObesityWeek 2014. Moderated by ConscienHealth’s Ted Kyle, presenters examined the problem of taking action when the evidence for the potential effects of action is incomplete. Bill Dietz — who led CDC efforts against […]
November 2, 2014 — ObesityWeek at its core is a meeting of the best scientists in obesity research coming together with clinicians and other stakeholders. So it’s tough to pick only five key sessions where you can find some of the best new science at ObesityWeek. But here’s our best shot anyway. If you have some sessions to recommend, hit […]
October 30, 2014 — Investing in obesity seems like it ought to be a rewarding proposition. So why is it so messy for so many investors? Are we on the brink of better results for investing in obesity? So far, the news has been decidedly mixed for people in businesses related to the surge in obesity rates. Food companies whose brands are […]
